|
|
||||||||||
|
J Am Coll Cardiol, 2007; 49:279-289, doi:10.1016/j.jacc.2006.08.051
(Published online 3 January 2007). © 2007 by the American College of Cardiology Foundation |
,1,*
* Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio
Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California.
Manuscript received March 15, 2006; revised manuscript received July 6, 2006, accepted August 28, 2006.
* Reprint requests and correspondence: Dr. Eric J. Topol, Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037. (Email: etopol{at}scripps.edu).
Acute coronary syndromes represent a complex phenotype involving the interplay of many elements. The risk of developing an acute coronary syndrome and related complications has been defined by variables such as age, diabetes, smoking history, serum creatine phosphokinase, or electrocardiographic findings. However, in the past 5 years the wide-scale acceptance of a proteintroponinhas changed the diagnostic profile. With advances in molecular medicine, this protein is a segue to a panel of molecular assays that will improve screening and tailored intervention. We expound upon some of these factors and the potential they may carry in changing clinical medicine.
| ||||||||||
This article has been cited by other articles:
![]() |
R. P. Giugliano and E. Braunwald The Year in Non ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1386 - 1395. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |